Ratings Surperformance

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
CCC

Ratings ESG MSCI

Ratings Vanda Pharmaceuticals Inc.: Strengths and Weaknesses

  • From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
  • The company has a poor ESG score according to MSCI, which ranks companies by sector.
Highlights: Vanda Pharmaceuticals Inc.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
  • The opinion of analysts covering the stock has improved over the past four months.
  • Consensus analysts have strongly revised their opinion of the company over the past 12 months.
  • The group usually releases upbeat results with huge surprise rates.
Weaknesses: Vanda Pharmaceuticals Inc.
  • The company's currently anticipated earnings per share (EPS) growth for the next few years is a notable weakness.
  • For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.

Rating Financials

Vanda Pharmaceuticals Inc. SectorUnited States

Fundamentals

-

Growth

Revenue growth

EPS growth

FCF growth

Profitability

EBITDA Margin

-

EBIT Margin

Net Margin

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

Long term EPS growth

More ratings

Rating Valuation

Vanda Pharmaceuticals Inc. SectorUnited States

Global Valuation

-

Enterprise value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

More ratings

Rating Consensus

Vanda Pharmaceuticals Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings

Rating Business Predictability

Vanda Pharmaceuticals Inc. SectorUnited States

Visibility

Analysts' coverage

Financial estimates divergence

Analysts' recommendations divergence

Analysts' Target price divergence

Surprise rates

Rating Revisions

Vanda Pharmaceuticals Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings

Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
387M -
CCC
- -
50.04B
A
48.62B
AAA
25.57B -
A
- -
23.32B - - - -
17.89B
AAA
16.2B
A
14.97B
B
14.58B - - - -
13.47B -
AA
- -
Average 22.51B
A
Weighted average by Cap.
A
  1. Stock Market
  2. Equities
  3. VNDA Stock
  4. Ratings Vanda Pharmaceuticals Inc.